Verizon Communications, Inc. (VZ) reported quarterly earnings, reporting adjusted earnings of $1.19 per share on revenue of $35.3 billion, both in-line with analysts’ estimates. Verizon expects adjusted profit between $4.55 per share and $4.85 per share in 2023, below market estimate of $4.97 per share. The telecom giant expects wireless service revenue to grow between 2.5% and 4.5% in 2023 after posting an 8.6% increase in 2022. Verizon added 416,000 broadband customers in the three months to December quarter.
The company forecast annual profit below expectations as the pandemic-led boom in wireless customer growth fizzles out and the company makes heavy investments in 5G technology. Verizon lost subscribers last year to its fast-growing rivals AT&T Inc and T-Mobile offering more affordable plans or with better 5G networks.
Verizon Communications, Inc. (VZ) is a worldwide leader in delivering communications and technology solutions that improve the lives of its customers. To learn more about Verizon Communications, Inc. (VZ) and track its progress, please visit the Vista Partners Verizon Communications Inc. Coverage Page.
Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.
On Wednesday Jan., 25, Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced the issuance of the following Letter to Shareholders from Steven C. Quay, M.D., Ph.D., the Company’s CEO and Chairman:
TO OUR VALUED STOCKHOLDERS:
2022 was a year of significant progress for Atossa. We focused our development efforts on advancing our breast cancer program with our patented (Z)-endoxifen, the highest potency Selective Estrogen Receptor Modifier (SERM). We currently have Phase 2 studies ongoing in the prevention and treatment settings, both focused on areas of unmet medical need. Our goal is to both help reduce the incidence of breast cancer and change the treatment paradigm for patients who are not benefiting from currently approved drugs.
In October 2022, the U.S. Food and Drug Administration (FDA) authorized the initiation of our EVANGELINE study, a Phase 2 trial of (Z)-endoxifen and Exemestane + Goserelin as neoadjuvant treatment in premenopausal women with ER+/HER2- breast cancer. While there are several FDA-approved neoadjuvant therapies for ER- breast cancers, few exist for the ER+ patients, which account for approximately 78% of breast cancers. We expect to enroll approximately 175 patients at up to 25 sites across the United States.